- ISIN
- US76243J1051
- CUSIP
- 76243J105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 5, 2017
Highlights
- Market Cap
- $7.22B
- Enterprise Value
- $7.16B
- EPS (TTM)
- -$3.10
- Total Revenue (TTM)
- $217.17M
- Gross Profit (TTM)
- $194.16M
- EBITDA (TTM)
- -$182.86M
- Year Range
- $60.80 - $122.20
- Target Price
- $140.00
- ROA (TTM)
- -46.07%
- ROE (TTM)
- -165.80%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RYTM Performance Chart
Rhythm Pharmaceuticals, Inc. (RYTM) is down 0.8% since the beginning of the year. At $106 per share, RYTM is trading 13.1% below its 52-week high of $122. Investors who bought $1,000 worth of RYTM shares 5 years ago would now be looking at an investment worth $5,074.
Loading charts...
Returns By Period
Rhythm Pharmaceuticals, Inc. (RYTM) has returned -0.79% so far this year and 70.92% over the past 12 months.
Rhythm Pharmaceuticals, Inc.
- 1D
- 4.73%
- 1M
- 20.89%
- YTD
- -0.79%
- 6M
- -5.48%
- 1Y
- 70.92%
- 3Y*
- 82.60%
- 5Y*
- 38.38%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
RYTM Monthly Returns History
Based on dividend-adjusted daily data since Oct 5, 2017, RYTM's average daily return is +0.17%, while the average monthly return is +4.09%. At this rate, an investment would double in approximately 1.4 years.
Historically, 47% of months were positive and 53% were negative. The best month was Jul 2022 with a return of +203.6%, while the worst month was Apr 2022 at -45.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, RYTM closed higher 50% of trading days. The best single day was Jul 12, 2022 with a return of +42.2%, while the worst single day was Sep 15, 2022 at -24.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.22% | -9.55% | -6.21% | -6.45% | 8.55% | 20.23% | -0.79% | ||||||
| 2025 | 6.16% | -7.61% | -3.53% | 23.07% | -5.92% | 3.03% | 34.88% | 21.03% | -2.09% | 12.64% | -4.11% | -1.88% | 91.21% |
| 2024 | -4.05% | -1.56% | -0.21% | -8.24% | -10.26% | 15.08% | 17.41% | -1.91% | 10.78% | -8.89% | 29.98% | -9.77% | 21.78% |
| 2023 | -6.08% | -11.12% | -26.61% | 13.06% | -17.40% | -1.02% | 8.19% | 45.80% | -11.86% | 0.81% | 44.66% | 37.51% | 57.86% |
| 2022 | -25.75% | 2.83% | 51.18% | -45.66% | -45.05% | 20.64% | 203.61% | 79.37% | 8.41% | 2.73% | 6.36% | 8.78% | 191.78% |
| 2021 | 3.23% | -15.54% | -17.94% | 1.36% | -9.04% | -0.15% | -11.70% | -24.75% | 0.38% | -11.87% | -22.24% | 11.51% | -66.43% |
Benchmark Metrics
Rhythm Pharmaceuticals, Inc. has an annualized alpha of 31.02%, beta of 1.08, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since October 05, 2017.
- This stock captured 116.44% of S&P 500 Index gains but only 93.73% of its losses - a favorable profile for investors.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 31.02%
- Beta
- 1.08
- R²
- 0.08
- Upside Capture
- 116.44%
- Downside Capture
- 93.73%
Return for Risk
Risk / Return Rank
RYTM ranks 78 for risk / return — better than 78% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Rhythm Pharmaceuticals, Inc. (RYTM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RYTM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.55 | ||
| Sortino ratioReturn per unit of downside risk | -0.11 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.32 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 2.01 | 2.46 | -0.45 |
| Martin ratioReturn relative to average drawdown | 4.57 | 10.92 | -6.35 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Rhythm Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Rhythm Pharmaceuticals, Inc. was 92.10%, occurring on May 19, 2022. Recovery took 393 trading sessions.
The current Rhythm Pharmaceuticals, Inc. drawdown is 9.72%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -92.10%May 2022 | 1y 3mo | 1y 6mo | 2y 10moJan 2021 - Dec 2023 |
COVID crash2020 | -63.29%Mar 2020 | 1y 8mo | 10mo 11d | 2y 6moJul 2018 - Jan 2021 |
2018 bear market2018 | -47.22%Apr 2018 | 2mo 2d | 2mo | 4mo 2dJan 2018 - Jun 2018 |
2026 bear market2026 | -35.54%Mar 2026 | 3mo 15d | — | 6mo 14dDec 2025 - now |
2024 bear market2024 | -32.48%May 2024 | 3mo 16d | 1mo 18d | 5mo 4dFeb 2024 - Jul 2024 |
Drawdown Indicators
| RYTM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.10% | -56.78% | -35.32% |
Max Drawdown (1Y)Largest decline over 1 year | -35.54% | -9.10% | -26.44% |
Max Drawdown (3Y)Largest decline over 3 years | -35.54% | -18.90% | -16.64% |
Max Drawdown (5Y)Largest decline over 5 years | -84.95% | -25.43% | -59.52% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -9.72% | -3.21% | -6.51% |
Average DrawdownAverage peak-to-trough decline | -32.11% | -10.71% | -21.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.58% | 2.04% | +13.54% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Rhythm Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Rhythm Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RYTM relative to other companies in the Biotechnology industry. Currently, RYTM has a P/S ratio of 32.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RYTM in comparison with other companies in the Biotechnology industry. Currently, RYTM has a P/B value of 880.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RYTM
Add Rhythm Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RYTM